Tirzepatide’s effectiveness in patients with heart failure and preserved pumping function

Tirzepatide use was associated with a 52% lower risk of heart failure exacerbation and all-cause mortality in patients with heart failure with preserved ejection fraction.

• In a cohort of 14,154 patients with heart failure with preserved ejection fraction, tirzepatide was linked to improved outcomes.
• The primary composite outcome showed a hazard ratio of 0.52 for heart failure exacerbation and all-cause mortality.
• Significantly lower risks were also observed for major adverse cardiovascular events (HR 0.64) and major adverse kidney events (HR 0.44).
• Subgroup analyses indicated consistent benefits across different patient groups.
• Sensitivity analyses validated the reliability of these findings.

Simplified